Decreased circulating vitamin D reflects adverse outcomes of hepatitis C virus infection: A systematic review and meta-analysis - 22/09/20
, Jiraphun Jittikoon a , Sorraya Sukkho a , Nicha Pojarassangkul a , Sermsiri Sangroongruangsri b , Usa Chaikledkaew b, c Highlights |
• | Reduced systemic vitamin D levels were found in HCV-infected patients. |
• | Systemic vitamin D levels were decreased in HCV-infected patients with adverse outcomes. |
• | Low vitamin D status was associated with HCV infection, severe fibrosis, and non-achieving SVR. |
• | Decreased systemic vitamin D would reflect adverse outcomes of HCV infection. |
• | Low vitamin D status could serve as a biomarker for adverse outcomes in HCV-infected patients. |
Summary |
Objectives |
This study aimed to clarify associations of circulating vitamin D and its status with severity of HCV infection.
Methods |
We performed systemic literature search in PubMed, Scopus, and Cochrane library databases from inception until the end of December 2019 with terms related to vitamin D and hepatitis C.
Results |
A total of 28 studies consisting of 7736 HCV-infected patients and 14061 control subjects without liver diseases were included. Compared to controls, circulating vitamin D levels were significantly lessened in HCV-infected patients (mean difference, MD=−14.15, 95% CI: −20.51 to −7.80). Remarkably decreased circulating vitamin D was found in the patients with severe fibrosis (MD=−3.38, 95% CI: −4.51 to −2.25), non-achieving SVR (MD=−2.99, 95%CI: −5.55 to −0.42), and advanced inflammation (MD=−4.68, 95% CI: −8.50 to −0.86). Low vitamin D status (<20 ng/mL) was significantly associated with increased odds of HCV infection (pooled OR=2.41, 95% CI: 1.48 to 3.95). Besides, HCV-infected patients with low vitamin D status showed significantly escalated odds of severe fibrosis and non-achieving SVR (pooled OR=1.70, 95% CI: 1.27 to 2.26; pooled OR=2.04, 95% CI: 1.62 to 2.57, respectively).
Conclusion |
HCV-infected patients with declined circulating vitamin D levels were associated with severe fibrosis, non-achieving SVR, and advanced inflammation.
Le texte complet de cet article est disponible en PDF.Keywords : Vitamin D, Hepatitis C, Liver fibrosis, Sustained virologic response, Hepatic inflammation
Plan
Vol 81 - N° 4
P. 585-599 - octobre 2020 Retour au numéro
Article précédent
- Geographically widespread invasive meningococcal disease caused by a ciprofloxacin resistant non-groupable strain of the ST-175 clonal complex
- Laura Willerton, Jay Lucidarme, Helen Campbell, Dominique A Caugant, Heike Claus, Susanne Jacobsson, Shamez N Ladhani, Paula Mölling, Arianna Neri, Paola Stefanelli, Muhamed-Kheir Taha, Ulrich Vogel, Ray Borrow
- GEHEP 010 study: Prevalence and distribution of hepatitis B virus genotypes in Spain (2000–2016)
- Antonio Aguilera, Rocío Trastoy, Francisco Rodríguez-Frias, Juan Luis Muñoz-Bellido, Santiago Melón, Avelina Suárez, Antonio Orduña, Isabel Viciana, Samuel Bernal, Silvia García-Bujalance, Natalia Montiel, José Manuel Molina, Miren Basaras, Felipe Fernández-Cuenca, Isabel García-Arata, Gabriel Reina, María Dolores Ocete, Ana Fuentes, Daniel Navarro-de la Cruz, Leonardo Nieto, Ana Blazquez de Castro, María Buti, Marta Álvarez, Federico García
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?